Jia, Xiaoming <br/><br/>
Eligibility and Cost for Icosapent Ethyl Based on the REDUCE-IT Trial.  [electronic resource] 

 -  Circulation  03 2019 
 - 1341-1343 p.  digital 
<br/><br/> Publication Type: Letter; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. 
<br/><br/><label>ISSN: </label>1524-4539 
<br/><br/><label>Standard No.: </label>10.1161/CIRCULATIONAHA.118.038691  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Atherosclerosis--blood<br/>Biomarkers--blood<br/>Clinical Decision-Making<br/>Clinical Trials as Topic<br/>Drug Costs<br/>Dyslipidemias--blood<br/>Eicosapentaenoic Acid--adverse effects<br/>Eligibility Determination--economics<br/>Humans<br/>Hypolipidemic Agents--adverse effects<br/>Lipids--blood<br/>Multicenter Studies as Topic<br/>Patient Selection<br/>Risk Factors<br/>Treatment Outcome<br/>United States--epidemiology<br/>United States Department of Veterans Affairs<br/>Veterans Health Services